Pharma
-
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape
Y-mAbs Therapeutics stunned investors when SERB Pharmaceuticals announced an all-cash bid to take the company private at $8.60 per share,…
Read More » -
Abbvie’s $1 Billion Gilgamesh Gambit: The Deal That Could Rewrite Its Future!
AbbVie’s recent confirmation that it’s in talks to acquire Gilgamesh Pharmaceuticals for roughly $1 billion underscores its unrelenting push to…
Read More » -
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?
Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning…
Read More » -
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the…
Read More » -
Hims & Hers Stock Plunges After Novo Nordisk Breakup: What Really Happened?
Hims & Hers Health saw its stock crash by over 35% in a matter of days after Novo Nordisk announced…
Read More » -
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused…
Read More » -
ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery
Enter Aspire Biopharma, Inc. (NASDAQ: ASBP), a pioneering company enhancing existing drugs with their patent-pending, soluble sublingual technology. By delivering…
Read More » -
Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech
SmallCaps Daily sits down with ASBP’s CEO Kraig Higginson to discuss the company's disruptive technology and the expected clinical and…
Read More » -
NanoViricides Recent Clinical Updates and Milestones Highlight Potential Investor Opportunities
NanoViricides, Inc. (NYSE American: NNVC), a pioneering, clinical-stage biopharmaceutical company, is disrupting the antiviral game with its innovative, first-in-class, nanoviricides®…
Read More » -
Decoded: Why Did Johnson & Johnson Spend $2 billion To Acquire Ambrx Biopharma?
In a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer…
Read More »
